MARKET

DCPH

DCPH

Deciphera Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

55.18
+1.35
+2.51%
Opening 11:31 02/25 EST
OPEN
54.06
PREV CLOSE
53.83
HIGH
55.24
LOW
53.89
VOLUME
106.11K
TURNOVER
--
52 WEEK HIGH
71.11
52 WEEK LOW
19.88
MARKET CAP
2.99B
P/E (TTM)
-13.9811
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of DCPH and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average DCPH stock price target is 69.36 with a high estimate of 84.00 and a low estimate of 53.00.

EPS

DCPH News

More
  • Deciphera Pharmaceuticals, Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference
  • Business Wire · 5d ago
  • Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock
  • Business Wire · 5d ago
  • AEM, CARG among premarket losers
  • Seeking Alpha - Article · 02/14 14:09
  • About to Buy Penny Stocks? Look at These 2 Companies First
  • MotleyFool.com · 02/14 13:45

Industry

Biotechnology & Medical Research
-2.42%
Pharmaceuticals & Medical Research
-1.49%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About DCPH

Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally administered kinase switch control inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, including glioblastoma multiforme (GBM), and other solid tumors driven by pan-KIT or PDGFR alpha. DCC-3014 is an orally administered, potent and highly selective inhibitor of colony stimulating factor receptor 1 (CSF1R). Rebastinib is an orally administered, potent and selective inhibitor of the TIE2 immunokinase. Rebastinib binds potently into the switch pocket of TIE2, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.
More

Webull offers kinds of Deciphera Pharmaceuticals Inc stock information, including NASDAQ:DCPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DCPH stock news, and many more online research tools to help you make informed decisions.